联合早报 © SPH Media Limited. Reproduced with permissionNational University Health System, whose participating institutions include National University Cancer Institute, Singapore (NCIS), NUS Saw Swee Hock School of Public Health and National University Hospital (NUH), is currently conducting a pilot study known as the PPGx (Pre-emptive Pharmacogenomics Programme) to enrol 2,000 participants by 2025, with the objective to get a sense of how the population reacts to common drugs.
Prof Goh Boon Cher, Senior Consultant, Department of Haematology-Oncology at NCIS explained that one of the study’s key objectives is to help doctors identify which drug and dosage work best for the patient and which type of drug to avoid. Dr Elaine Lo, Lead Pharmacist of the PGx pilot and Principal Clinical Pharmacist, NUH shared that study outcomes, if positive, could provide the team with sufficient basis to convince the relevant authorities to incorporate PPGx as an approved approach towards precision medicine.
Lianhe Zaobao interviewed an NCIS patient living with an autoimmune disease who took part in the study, where she emphasised the importance of understanding genetic predispositions to medication reactions for individualised treatment.
Media ArticlesNUH in the NewsNCIS in the NewsNUHS in the News